SenesTech (NASDAQ: SNES) is one of 192 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare SenesTech to similar companies based on the strength of its dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.
Risk and Volatility
SenesTech has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, SenesTech’s competitors have a beta of 1.45, suggesting that their average share price is 45% more volatile than the S&P 500.
This table compares SenesTech and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current ratings and target prices for SenesTech and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SenesTech currently has a consensus price target of $8.50, indicating a potential upside of 1,131.88%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 19.56%. Given SenesTech’s stronger consensus rating and higher possible upside, equities analysts plainly believe SenesTech is more favorable than its competitors.
Institutional & Insider Ownership
15.3% of SenesTech shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 27.4% of SenesTech shares are owned by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares SenesTech and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|SenesTech Competitors||$227.13 million||-$38.90 million||-54.57|
SenesTech’s competitors have higher revenue, but lower earnings than SenesTech.
SenesTech beats its competitors on 7 of the 12 factors compared.
SenesTech Company Profile
SenesTech, Inc. is a United States-based biotechnology platform and research company. The Company is engaged in developing a technology for managing animal populations by fertility control. It offers ContraPest, a fertility control product candidate. ContraPest’s technology and approach targets the reproductive capabilities of both sexes. Using bait stations, ContraPest is dispensed in a palatable liquid formulation that promotes sustained consumption by rodent communities. Its formulation causes both female and male rats to become infertile once they have consumed the dose. The active ingredient in females accelerates the rate at which ovarian follicles (egg structures) are depleted. Once these cells are gone, the animal cannot reproduce. In males, there is a marked reduction in the ability to fertilize eggs and, often complete sterility. ContraPest is designed, formulated and dispensed for handlers and non-target species, such as wildlife and pets in a biodegradable product.
Receive News & Ratings for SenesTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SenesTech and related companies with MarketBeat.com's FREE daily email newsletter.